Rinzasip

Rinzasip – the combined medicine for a symptomatic treatment of acute respiratory diseases.

Form of release and structure

Rinzasip is issued in the form of powder for preparation of solution for intake:

• Orange powder: from light orange till orange color, with impregnations of white and orange color and an orange flavor (on 5 g in a sachet, in a cardboard pack of 5, 10, 25, 50 or 100 sachets);
• Lemon powder: from light yellow till yellow color, with impregnations of white and yellow color and lemon taste (on 5 g in a sachet, in a cardboard pack of 5, 10, 25, 50 or 100 sachets);
• Blackcurrant powder: from pink till pinkish-red color, with impregnations of white and red color and blackcurrant taste (on 5 g in a sachet, in a cardboard pack of 5, 10, 25, 50 or 100 sachets).

Structure of 5 g (1 sachet) of powder:

• Active ingredients: caffeine – 30 mg, Phenylephrinum a hydrochloride – 10 mg, paracetamol – 750 mg, pheniramine a maleate – 20 mg;
• Auxiliary components: sodium citrate, citric acid anhydrous, sucrose, sodium saccharin, dyes and fragrances (for powder with an orange flavor: orange flavoring substance, dye sanst yellow FCF; for powder with lemon taste: lemon flavoring substance, dye quinoline yellow; for powder with taste of blackcurrant: blackcurrant, crimson and fruit flavoring substance, dye кармоизин).

Indications to use

Powder Rinzasip is applied to a symptomatic treatment of a SARS, flu and other catarrhal diseases (for reduction of a feverish syndrome, pain and a rhinorrhea).

Contraindications

Absolute:

• Children's and teenage age up to 15 years;
• Pregnancy period;
• Feeding period breast;
• Simultaneous use of other drugs which part active ingredients of powder Rinzasip are;
• Simultaneous use of beta adrenoblockers, tricyclic antidepressants and monoamine oxidase inhibitors;
• Hypersensitivity to the main or auxiliary components of medicine.

Relative (Rinzasip apply with care):

• Arterial hypertension;
• Bronchial asthma;
• The expressed atherosclerosis of coronary arteries;
• Diabetes mellitus;
• Pheochromocytoma;
• HOBL (chronic obstructive pulmonary disease);
• Hereditary hyperbilirubinemias (syndrome Cudgel Johnson, Rotor and Gilbert);
• Thyrotoxicosis;
• Blood diseases (anemias, thrombocytopenia, hemorrhagic diathesis, etc.);
• Closed-angle form of glaucoma;
• Deficit of enzyme glyukozo-6-fosfatdegidrogenazy;
• Renal and/or liver failure;
• Prostate hyperplasia.

Route of administration and dosage

Drug Rinzasip is accepted inside with a large amount of water or other liquid in 1-2 hours after meal. For solution preparation contents of one sachet are filled in with one glass of hot water and carefully mixed before full dissolution of powder. At will it is possible to add honey or sugar.

To adult patients and teenagers 15 years are more senior appoint on 1 bag of drug 3-4 times a day. It is necessary to observe an interval between powder receptions Rinzasip. It has to make not less than 4-6 hours. The maximum dose – 4 sachets a day. Therapy duration – no more than 5 days.

Side effects

• Alimentary system: pains in epigastriums, dryness in a mouth, nausea, a hepatotoxic action, a lock;
• Cardiovascular system: tachycardia, increase in arterial pressure;
• Central nervous system: hyperexcitability, dizziness, accommodation paresis, backfilling disturbance, increase in VGD (intraocular pressure), mydriasis;
• Urinary system: toxic damage of kidneys, ischuria;
• Hemopoietic system: agranulocytosis, aplastic anemia, pancytopenia, anemia, methemoglobinemia, thrombocytopenia, hemolitic anemia;
• Allergic reactions: urticaria, a skin itch, a Quincke's disease, rash on skin;
• Other reactions: It is BAREFOOT (a bronkhoobstruktivny syndrome).

Special instructions

During treatment by drug it is necessary to refrain from reception anxiolytic or hypnagogues and alcohol intake.

Joint appointment with other drugs which part paracetamol is is forbidden.

If in 3-5 days of use of powder Rinzasip the condition of the patient does not improve, it is necessary to see a doctor.

During treatment it is necessary to perform the work demanding high concentration of attention and bystry reaction with extra care.

Medicinal interaction

Rinzasip strengthens effect of ethanol, sedative drugs and monoamine oxidase inhibitors.

At simultaneous use with the protivoparkinsonichesky means, antidepressants derivative of a fenotiazin and antipsychotic drugs the risk of emergence of dryness in a mouth, an ischuria and locks increases; with glucocorticosteroids – the probability of development of glaucoma increases; with diuretics – their efficiency decreases; with barbiturates, rifampicin, carbamazepine, dipheninum – the risk of manifestation of a hepatotoxic action of paracetamol increases.

Rinzasip reduces anti-hypertensive action of a guanetidin, and the last strengthens alpha адреностимулирующий effect of Phenylephrinum.

At joint appointment with a halothane the probability of development of ventricular arrhythmia increases, with tricyclic antidepressants – adrenomimetichesky action of Phenylephrinum amplifies.

Terms and storage conditions

To store in the dry place at a temperature no more than 25 °C. To protect from children. A period of validity – 3 years.